Since September of 2014I have been working with Dr Andrew Lane at Dana-Farber Cancer Insitute . We are currently focused on understanding how the nucleosome binding proteing HMGN1 affects myeloid differentiation and how it may be promoting AML development. By developing epigenetics studies and analysis of chromatin compaction and chemical modification of histones modifications we aim to elucidate new therapeutic approaches for treatment.